Akintunde Bello
Bristol-Myers Squibb (United States)(US)Kano State PolytechnicUsmanu Danfodiyo University(NG)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Health Systems, Economic Evaluations, Quality of Life, Renal cell carcinoma treatment, Economic and Financial Impacts of Cancer
Most-Cited Works
- → Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma(2012)275 cited
- → Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors(2017)232 cited
- → Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer(2018)201 cited
- → Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug(2011)147 cited
- → Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors(2017)120 cited
- → Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer(2017)98 cited